Annexes to the Vaccines and immunization for monkeypox interim guidance

Abstract

Annex 1: Summary of findings: Primary preventive vaccination with ACAM2000 compared to no vaccination for persons with a high risk of exposure to monkeypox;
Annex 2: Summary of findings: Primary preventive vaccination with MVA-BN compared to no vaccination for persons with a high risk of exposure to monkeypox;
Annex 3: Summary of findings: Primary preventive vaccination with LC16m8 compared to no vaccination for persons with a high risk of exposure to monkeypox;
Annex 4: Summary of findings: Primary preventive vaccination with MVA-BN compared to vaccination with ACAM2000 for persons with a high risk of exposure to monkeypox;
Annex 5: Evidence to recommendation framework: ACAM2000 for primary preventive vaccination;
Annex 6: Evidence to recommendation framework: LC16m8 for primary preventive vaccination;
Annex 7: Evidence to recommendation framework: MVA-BN for primary preventive vaccination;
Annex 8: Evidence to recommendation framework: ACAM2000, LC16m8, MVA-BN for post exposure preventive vaccination.